Ortho device panel preview
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopaedic Rehabilitation Devices Panel will convene Aug. 31 to review St. Francis Medical's PMA for the X-Stop interspinous process distraction system for non-fusion treatment of lumbar spinal stenosis, a degenerative disorder causing reduced mobility and pain usually treated with spinal fusion. The PMA is based on a 200-patient randomized trial comparing X-Stop to non-operative therapy. In the study, efficacy is measured as improvement in pain symptoms and increase in physical function and mobility...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.